Notice of Allowability	Application No.	Applicant(s)
	09/640,530	DENINNO ET AL.
	Examiner	Art Unit
	L. E. Crane	1623
The MAILING DATE of this communication appearance All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication GHTS. This application is subject to	olication. If not included will be mailed in due course. THIS
1. A This communication is responsive to amendment filed April	<u>12, 2004</u> .	
2. The allowed claim(s) is/are 41-48.		
3. The drawings filed on are accepted by the Examine	r.	•
4.		
Attachment(s)  1. Notice of References Cited (PTO-892)  2. Notice of Draftperson's Patent Drawing Review (PTO-948)  3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview Summary Paper No./Mail Date 8), 7. ⊠ Examiner's Amendm	e <u>06292004</u> .

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. §1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

The Abstract is replaced in its entirety by the following:

-- Compounds represented by Formula I and pharmaceutical compositions

containing same are disclosed. The disclosed compounds are effective for the treatment of tissue damage resulting from ischemia or hypoxia when administered to a mammalian host in need thereof.--.

Authorization for this Examiner's Amendment was given in a telephone interview with Mr. Marvin Bressler on June 29, 2004.

Papers related to this application may be submitted to Group 1600 via facsimile transmission (FAX). The transmission of such papers must conform with the notice published in the Official Gazette (1096 OG 30, November 15, 1989). The telephone number to FAX (unofficially) directly to Examiner's computer is 571-273-0651. The telephone number for sending an Official FAX to the PTO is 703-872-9306.

Any inquiry concerning this communication or earlier communications from the

Application/Control Number: 09/640,530

Art Unit: 1623

examiner should be directed to Examiner L. E. Crane whose telephone number is 571-272-0651. The examiner can normally be reached between 9:30 AM and 5:00 PM, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson, can be reached at 571-272-0661.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is **571-272-1600**.

All Post-Allowance Correspondence concerning this application must be mailed to:

BOX ISSUE FEE COMMISSIONER FOR PATENTS WASHINGTON, DC 20231

OR you can FAX them to the Office of Patent Publications at 703-308-5083, in order to expedite the handling of such correspondence as amendments under 37 C.F.R. §1.312; Information Disclosure Statements (IDS's), and formal drawings. Sending Post-Allowance papers to Technology Center 1600 will only cause <u>delays</u> in matching papers with the case.

For information concerning status of correspondence sent after receipt of the Notice of Allowance, please contact the Correspondence Branch at <u>703-305-8027</u>. The Notice of Allowance also has an insert containing contact information of other items, including Issue Fees, receipt of formal drawings, and the status of the application.

LECrane:lec **06/29/2004** 

L. E. Crane, Ph.D., Esq.

Primary Patent Examiner

Technology Center 1600